THOUSAND OAKS, Calif., May 17, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

Review the current Atara Biotherapeutics Inc (ATRA:XNAS) dividend yield and history to decide if ATRA is the best investment for you.

Zura Bio (ZURA) has announced the appointment of Eric Hyllengren as CFO, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a ...

Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway ...

See Atara Biotherapeutics, Inc. (ATRA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Get the latest news and real-time alerts from Atara Biotherapeutics, Inc. (ATRA) stock at Seeking Alpha.

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

Review the current Artiva Biotherapeutics Inc (ARTV:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if ARTV is the best investment for you.

Stealth BioTherapeutics' filing for rare disease drug elamipretide has been turned down by the FDA, although the company says the US regulator has given it a "path forward" for the programme ...